Azenta, Inc.
AZTAHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Azenta, Inc. focuses on Medical Instruments & Supplies services and products. Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific,. Valued at $1.60B, AZTA is a small-cap name in its sector. It operates through Sample Management Solutions and Multiomics segments.
Market Cap
$1.60B
Beta
1.52
P/E (TTM)
—
P/E (Fwd)
66.06
EPS (TTM)
$-2.42
EPS (Fwd)
$0.55
ROE
-7.0%
ROA
-0.7%
Cash
$325.8M
Total Debt
$54.0M
Free CF
$63.4M
52W Change
13.1%
Annual Financials
Cash vs Debt
Where AZTA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AZTA finished 28.28% above its 150-day moving average ($27.16) and 22.98% above its 200-day moving average ($28.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AZTA overbought or oversold?
At the October 20, 2026 close, AZTA's RSI(14) was 51.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $325.8M in cash and $54.0M in debt, AZTA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $63.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -7.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $555.5M (2022) to $593.8M (2025).
Azenta, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, AZTA has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing AZTA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.